Stay On Top of New Treatments for Ulcerative Colitis

January 2024

There’s a growing number of meds for ulcerative colitis (UC) now that mirikizumab (Omvoh) and upadacitinib (Rinvoq) are in the mix.

Injectable mirikizumab works similar to ustekinumab (Stelara) or risankizumab (Skyrizi) for Crohn’s...but mirikizumab is the first of this class to be approved for ulcerative colitis.

Oral upadacitinib is a “Janus kinase (JAK) inhibitor” already approved for rheumatoid arthritis and other conditions. Now it’s approved for moderate to severe UC...after the other JAK inhibitor, tofacitinib (Xeljanz, etc).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote